Cosmos Health Inc (COSM)

Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives

KEY HIGHLIGHTS Cana Laboratories, Cosmos Health's wholly owned subsidiary, acquires international patent...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories

Oliv18™ expands the 18 Series with a USDA and EU organic certified, 100% solvent-free, whole olive polyphenol...

Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz

CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM...

Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value

Company identifies real estate, digital assets, and marketable securities, among others, as potential sources...

Form DEF 14A - Other definitive proxy statements

Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price

Significant Deleveraging: Total liabilities decreased by $4.5 million, or 9.6%, quarter-over-quarter, while...

Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657

CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”...

Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation

Revenue increasing 207% at a 32% CAGR: From $65.3 million in 2025 to $200.6 million by 2029, driven by strong...

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form RW - Registration Withdrawal Request

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]